A unit of New Brunswick-based Johnson & Johnson will work with a unit of GlaxoSmithKline on developing a single-tablet HIV regimen.
ViiV Healthcare, owned by Glaxo, announced Thursday that it will work with Janssen R&D Ireland, owned by J&J, to develop and commercialize a pill that combines human immunodeficiency virus medicines from both companies.
Studies are expected to begin by the first quarter of 2015, according to a news release.
“New options that advance current therapies are increasingly important as patients and clinicians consider HIV care over the long term,” Dr John Pottage, chief medical officer, ViiV Healthcare, said in the release. “Through this collaboration with Janssen we aim to develop a new combination therapy that meets the needs of patients.”
ALSO ON NJBIZ:
Please note: All comments will be reviewed and may take up to 24 hours to appear on the site.View Comment Policy